Stockreport

Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies

ARYA Sciences Acquisition Corp III - Class A Ordinary Shares  (ARYA) 
PDF Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust accountLeading institutio [Read more]